- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Medicus Pharma Ltd: Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony | 777 | ACCESS Newswire | PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing... ► Artikel lesen | |
| Do | Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix Long-Term Economic and Development Profile | 1 | GlobeNewswire (USA) | ||
| 20.01. | Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026 | 1 | GlobeNewswire (USA) | ||
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 05.01. | Medicus Pharma to present phase 2 data at Biotech Showcase 2026 | 2 | Investing.com | ||
| 05.01. | Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates | 2 | GlobeNewswire (USA) | ||
| 30.12.25 | Medicus Pharma startet "At-the-Market"-Eigenkapitalprogramm über bis zu 15,3 Mio. US-Dollar | 1 | Investing.com Deutsch | ||
| 30.12.25 | Medicus Pharma Ltd. - 8-K, Current Report | - | SEC Filings | ||
| 22.12.25 | Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence Driven Clinical Data Analytics Platform | 535 | ACCESS Newswire | The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute urinary... ► Artikel lesen | |
| 17.12.25 | Medicus Pharma completes patient enrolment for basal cell carcinoma trial | 1 | PMLiVE | ||
| 15.12.25 | Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin | 179 | GlobeNewswire (Europe) | THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026... ► Artikel lesen | |
| 08.12.25 | Medicus Pharma Ltd. - 8-K, Current Report | - | SEC Filings | ||
| 05.12.25 | Medicus Pharma sichert sich 5,1 Mio. US-Dollar durch Optionsschein-Vereinbarung | 2 | Investing.com Deutsch | ||
| 05.12.25 | Medicus Pharma secures $5.1 million from warrant exercise agreement | 1 | Investing.com | ||
| 05.12.25 | Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement | 378 | ACCESS Newswire | Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA / ACCESS Newswire / December 5, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company")... ► Artikel lesen | |
| 01.12.25 | Medicus Pharma Appoints President Carolyn Bonner CFO | 3 | RTTNews | ||
| 01.12.25 | Medicus Pharma appoints Carolyn Bonner as president and CFO | 1 | Investing.com | ||
| 01.12.25 | Medicus Pharma appoints Carolyn Bonner as CFO after Quinlan resigns | 1 | Investing.com | ||
| 01.12.25 | Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President | 259 | ACCESS Newswire | Carolyn Bonner Succeeds James ('Jim') Quinlan Who Has Resigned for Health Reasons After Taking Medical Leave in September 2025 PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 1, 2025 / Medicus... ► Artikel lesen | |
| 01.12.25 | Doppelrolle bei Medicus Pharma: Carolyn Bonner wird Präsidentin und CFO | - | Investing.com Deutsch | ||
| 01.12.25 | Medicus Pharma ernennt Präsidentin Carolyn Bonner zur neuen Finanzchefin | - | Investing.com Deutsch |
1 2 3 4 Weiter >>
76 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,800 | +0,14 % | Dividendenbekanntmachungen (23.01.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALBERTSONS COMPANIES INC US0130911037 0,15 USD 0,1275 EUR BANK OF NEW YORK MELLON CORPORATION US0640581007 0,53 USD 0,4508 EUR COCA-COLA... ► Artikel lesen | |
| GILEAD SCIENCES | 116,88 | +0,76 % | Gilead Sciences stock price target raised to $150 by BMO Capital | ||
| ELI LILLY | 896,80 | +0,26 % | AKTIONÄR-Tipp Camurus: "Top-Pick" - mit Eli Lilly in neue Dimensionen | Die Aktie des schwedischen Biotech-Unternehmens Camurus hat sich in den zurückliegenden Monaten sehr volatil entwickelt. Die Analysten von ABG Sundal Collier (ABGSC) trauen dem Papier allerdings neue... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 403,15 | +0,45 % | Breaking Down Vertex Pharmaceuticals: 12 Analysts Share Their Views | ||
| EYEPOINT | 12,900 | -0,73 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 | - Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 10,500 | -1,87 % | BioCryst Pharmaceuticals, Inc.: BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema | RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 168,00 | +0,60 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 139,35 | -0,29 % | Boehringer Ingelheim Limited: Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer | Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients
Ingelheim, Germany- 12 January, 2026 - Boehringer Ingelheim today announced a strategic... ► Artikel lesen | |
| OPKO HEALTH | 1,096 | +0,59 % | OPKO Health, Inc.: OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results | MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights... ► Artikel lesen | |
| UNITED THERAPEUTICS | 399,00 | +0,88 % | United Therapeutics reports positive phase 1 results for bioengineered liver | ||
| ROYALTY PHARMA | 33,930 | -0,38 % | Royalty Pharma plc: Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 | ||
| CATALYST PHARMACEUTICALS | 20,410 | +1,09 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 65,12 | -0,55 % | BridgeBio Pharma, Inc. - 8-K, Current Report | ||
| TG THERAPEUTICS | 25,845 | +0,12 % | After-Hours Biotech Rally: SXTC, RPID, TGTX Lead Gains On Revenue Updates, And FDA Milestones | BEIJING (dpa-AFX) - Several biotechnology and pharmaceutical names posted notable gains in Tuesday's after-hours trading session, driven by corporate updates and investor enthusiasm around clinical... ► Artikel lesen | |
| AVADEL PHARMACEUTICALS | 18,100 | -0,55 % | Lundbeck 'not willing to compromise' on M&A strategy after missed Avadel attempt: exec |
Das Unternehmen MEDICUS PHARMA LTD kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 1,230 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.